{"id":25994,"date":"2022-04-26T11:03:34","date_gmt":"2022-04-26T09:03:34","guid":{"rendered":"https:\/\/cio.umh.es\/?p=25994"},"modified":"2022-09-26T12:19:26","modified_gmt":"2022-09-26T10:19:26","slug":"alvarez-h-et-al-175-2022-predictors-of-low-level-hiv-viraemia-and-virological-failure-in-the-era-of-integrase-inhibitors-a-spanish-nationwide-cohort-hiv-medicine-2","status":"publish","type":"post","link":"https:\/\/cio.umh.es\/en\/2022\/04\/26\/alvarez-h-et-al-175-2022-predictors-of-low-level-hiv-viraemia-and-virological-failure-in-the-era-of-integrase-inhibitors-a-spanish-nationwide-cohort-hiv-medicine-2\/","title":{"rendered":"\u00c1lvarez, H. et al. (175) (2022) \u201cPredictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort\u201d, HIV Medicine, 23 (8):825\u2013836"},"content":{"rendered":"<p class=\"AuthorHeader-module__syvlN margin-size-4-t\" style=\"text-align: justify\"><strong>Hortensia \u00c1lvarez (Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, A Coru\u00f1a, Spain) et al. (175)<\/strong><\/p>\n<p class=\"AuthorHeader-module__syvlN margin-size-4-t\" style=\"text-align: justify\"><strong>Abstract:<\/strong> <span>Objectives: To pinpoint factors associated with low-level viraemia (LLV) and virological failure (VF) in people living with HIV in the era of high-efficacy antiretroviral treatment (ART) and widespread use of integrase strand transfer inhibitor (INSTIs)-based ART. Methods: We included adults aged &gt;\u00a018\u00a0years starting their first ART between 2015 and 2018 in the Spanish HIV\/AIDS Research Network National Cohort (CoRIS). Low-level viraemia was defined as plasma viral load (pVL) of 50\u2013199 copies\/mL at weeks 48 and 72 and VF was defined as pVL \u2265\u00a050 copies\/mL at week 48 and pVL \u2265\u00a0200 copies\/mL at week 72. Multivariable logistic regression models assessed the impact on LLV and VF of baseline CD4 T-cell count, CD4\/CD8 T-cell ratio and pVL, initial ART classes, age at ART initiation, time between HIV diagnosis and ART initiation, gender and transmission route. Results: Out of 4186 participants, 3120 (76.0%) started INSTIs, 455 (11.1%) started boosted protease inhibitors (bPIs) and 443 (10.8%) started nonnucleoside reverse transcriptase inhibitors (NNRTIs), either of them with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs). Low-level viraemia was met in 2.5% of participants and VF in 4.3%. There were no significant differences throughout the years for both virological outcomes. Baseline HIV-1 RNA &gt;\u00a05\u00a0log<\/span><sub>10<\/sub><span>\u00a0copies\/mL was the only consistent predictor of higher risk of LLV [adjusted odds ratio (aOR) = 9.8, 95% confidence interval (CI): 2.0\u201348.3] and VF (aOR = 5.4, 95%\u00a0CI: 1.9\u201315.1), even in participants treated with INSTIs. Conclusions: The rates of LLV and VF were low but remained steady throughout the years. Baseline HIV-1 RNA &gt;\u00a05\u00a0log<\/span><sub>10<\/sub><span>\u00a0copies\/mL showed a persistent association with LLV and VF even in participants receiving INSTIs.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Hortensia \u00c1lvarez (Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, A Coru\u00f1a, Spain) et al. (175)<br \/>\nAbstract: Objectives: To pinpoint factors associated with low-level viraemia (LLV) and virological failure (VF) in people living with HIV in the era of high-efficacy antiretroviral treatment (ART) and widespread use of integrase strand transfer inhibitor (INSTIs)-based ART. [&#8230;]<\/p>","protected":false},"author":5675,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_links_to":"","_links_to_target":""},"categories":[369888],"tags":[],"_links":{"self":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/posts\/25994"}],"collection":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/users\/5675"}],"replies":[{"embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/comments?post=25994"}],"version-history":[{"count":0,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/posts\/25994\/revisions"}],"wp:attachment":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/media?parent=25994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/categories?post=25994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/tags?post=25994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}